Potentiodynamic polarization curves for P110 carbon steel corrosion in the absence and presence of different concentrations of (a) 5, (b) 6a and (c) 6b. by Ghadeer Mubarak (21567569)

A Functional 12T-Insertion Polymorphism in the <i>ATP1A1</i> Promoter Confers Decreased Susceptibility to Hypertension in a Male Sardinian Population by Victoria L. Herrera (383897)

Subjects:

Decreased weight loss in FI-A2 and G-A2 peptide vaccinated mice after RSV challenge. by Gertrud U. Rey (501694)

SEM images (at 100x) of (a-1) polished P110 CS and corroded in 15% HCl for 6h (a) in the absence and presence of (b) 5, (c) 6a and (d) 6b. by Ghadeer Mubarak (21567569)

Genetic information on 5 subjects carrying <i>NR5A1</i> mutations. by Jana Malikova (615672)

Subjects:

EmSFRP expression is decreased in sponges treated with dsRNA to EmPaxB. by Chelsea Hall (6392540)

What is the Optimal Size of the Quantum Region in Embedding Calculations of Two-Photon Absorption Spectra of Fluorescent Proteins? by Dawid Grabarek (2617847)

Subjects:

<i>SIRT6</i> Minor Allele Genotype Is Associated with >5-Year Decrease in Lifespan in an Aged Cohort by Mindi J. TenNapel (679433)

Integrin expression decreased in treated tumors. by Anthony B. Eason (6294305)

D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis. by Kristine C. McGrath (8269155)

D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis. by Kristine C. McGrath (8269155)

Table_1_Loneliness as a mediation from social support leading to a decrease of health-related quality of life among PLWHIV.docx by Zhe Qian (509424)

“…The model showed loneliness as a mediation from social support leading to a decrease of HRQoL. …”

Table_2_Loneliness as a mediation from social support leading to a decrease of health-related quality of life among PLWHIV.docx by Zhe Qian (509424)

“…The model showed loneliness as a mediation from social support leading to a decrease of HRQoL. …”

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects: